We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+21.76%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.27B
AUM Growth
+$51.2M
Cap. Flow
-$77.3M
Cap. Flow %
-6.08%
Top 10 Hldgs %
71.44%
Holding
50
New
3
Increased
6
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$76.3M
2
ADVM
Adverum Biotechnologies
ADVM
+$22.8M
3
DYN icon
Dyne Therapeutics
DYN
+$13.6M
4
SLN
Silence Therapeutics
SLN
+$12.9M
5
RGLS
Regulus Therapeutics
RGLS
+$8.15M

Top Sells

Rank Stock Value
1
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$95.8M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$35.8M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$26.9M
4
APGE icon
Apogee Therapeutics
APGE
+$11.2M
5
VRNA
Verona Pharma
VRNA
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$360M 28.31%
8,418,093
– –
GERN icon
2
Geron
GERN
$930M
$89.8M 7.06%
27,225,292
+3,081,611
+13% +$6.9M
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$87.5M 6.88%
2,606,247
– –
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
$76.3M 6%
+11,800,000
New +$76.3M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$67.1M 5.27%
3,972,099
-124,329
-3% -$1.85M
VRNA
6
DELISTED
Verona Pharma
VRNA
$58.1M 4.56%
3,610,177
-639,741
-15% -$11.1M
ALXO icon
7
ALX Oncology
ALXO
$268M
$47.1M 3.7%
4,220,048
– –
DYN icon
8
Dyne Therapeutics
DYN
$4.28B
$46.4M 3.65%
1,635,136
+600,000
+58% +$13.6M
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$43.7M 3.43%
6,657,992
– –
ATXS
10
DELISTED
Astria Therapeutics
ATXS
$32.8M 2.58%
2,329,027
-153,700
-6% -$1.91M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.15B
$29.4M 2.31%
1,678,207
– –
SLN
12
Silence Therapeutics
SLN
$546M
$23.9M 1.88%
1,105,454
+595,250
+117% +$12.9M
OLMA icon
13
Olema Pharmaceuticals
OLMA
$1.01B
$21.2M 1.67%
1,873,704
– –
ADVM
14
DELISTED
Adverum Biotechnologies
ADVM
$21.2M 1.67%
+1,500,000
New +$22.8M
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
$20.8M 1.63%
520,505
-298,770
-36% -$8.82M
TARS icon
16
Tarsus Pharmaceuticals
TARS
$2.57B
$20.6M 1.62%
565,550
-1,218,456
-68% -$35.8M
VSTM icon
17
Verastem
VSTM
$547M
$18.2M 1.43%
1,538,461
– –
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.88B
$16.4M 1.29%
350,000
– –
COGT icon
19
Cogent Biosciences
COGT
$6.95B
$15.1M 1.19%
2,244,941
– –
SERA icon
20
Sera Prognostics
SERA
$79.5M
$15M 1.18%
1,650,440
– –
RGLS
21
DELISTED
Regulus Therapeutics
RGLS
$14.4M 1.13%
+5,000,000
New +$8.15M
TRML
22
DELISTED
Tourmaline Bio
TRML
$13.6M 1.07%
591,882
– –
CMPS
23
Compass Pathways
CMPS
$1.46B
$13.4M 1.05%
1,608,000
– –
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.23B
$11.7M 0.92%
849,681
– –
ENGN icon
25
enGene Therapeutics
ENGN
$118M
$11.5M 0.9%
678,705
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vivo Capital held 50 positions worth $1.27B, up 4.2% from $1.22B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Vivo Capital withdrew a net $77.3M in Q1 2024, closing 8 positions and reducing 7 holdings. Its most notable exit was Gracell Biotechnologies Inc. American Depositary Shares, an estimated $95.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Sinovac Biotech, Ltd worth $76.3M.

  • Vivo Capital's largest Q1 2024 buy was Sinovac Biotech, Ltd: 11,800,000 shares worth $76.3M.
  • Vivo Capital added most to Dyne Therapeutics in Q1 2024, an estimated $13.6M increase.
  • Vivo Capital's biggest Q1 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $35.8M.
  • Vivo Capital fully exited Gracell Biotechnologies Inc. American Depositary Shares in Q1 2024, selling an estimated $95.8M.
  • Vivo Capital's ten largest holdings make up 71% of its $1.27B portfolio in Q1 2024.
  • Vivo Capital opened 3 new positions and closed 8 in Q1 2024.
  • Vivo Capital's portfolio value rose 4.2% quarter-over-quarter to $1.27B.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.